PARP1 and ovarian carcinoma: This study demonstrates that the resveratrol analogue, trans‐4,4′‐dihydroxystilbene (DHS), exhibits synergistic anti‐tumor activity with the PARP inhibitor talazoparib, inducing significant ovarian cancer cell death.